ReviewFrontiers in oncology2026
Comprehensive overview of management and risk assessment of breast cancer-related lymphedema: a multidisciplinary approach.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Objective Severity, Pain and Range-of-Motion Limitation in Breast Cancer-Related Upper-Limb Lymphedema: Associations with Patient-Reported Burden.Journal of clinical medicine · 2026Article
- Ultrasound-Guided Axillary Management in Early-Stage Breast Cancer: From Diagnosis to De-Escalation.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most commonly diagnosed cancers worldwide, with a particularly high incidence in women. Although many are cured of their malignancy, treatment options can present with significant long-term complications for the patient. Lymphedema is the accumulation of protein-rich fluid that occurs following a disturbance to the lymphatic system. Secondary lymphedema to the arm often results following breast surgery or axillary lymph node dissection, although risk and exacerbating factors include radiation and medical chemotherapy, both in the short- and long-term intervals. Breast cancer-related lymphedema (BCRL) develops secondary to treatment-related lymphatic injury, commonly involving the axillary lymphatic system, with clinical manifestations that may affect the ipsilateral arm, hand, breast, chest wall, and axilla. This article serves as an updated and comprehensive review of the available peer-reviewed literature regarding the pathophysiology, incidence, predictive/risk factors, clinical features, diagnostic strategies, comparative accuracy and utility of early detection and surveillance approaches, preventive strategies, and guidelines-based conservative/surgical/emerging management approaches for BCRL. The purpose of this review is to apprise healthcare professionals with the latest understanding of optimal care and counseling patients regarding BCRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.